Forward Pharma A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FWPAY research report →
About the company
Forward Pharma A/S presently engages in very limited business activities. In the past, this biopharmaceutical firm concentrated its efforts on developing FP187, its distinctive formulation of dimethyl fumarate, which was aimed at addressing both inflammatory and neurological conditions. The company was founded in 2005 and its headquarters are located in Copenhagen, Denmark.
- CEO
- Claus Bo Søndergaard Svendsen
- IPO
- 2014
- Employees
- 4
- HQ
- Copenhagen, DK
Price Chart
- Market Cap
- $7.45M
- P/E
- 2166.67
- P/S
- 0.00
- P/B
- 2.69
- EV/EBITDA
- 37.40
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- 2060.64%
- Net Margin
- -47.87%
- ROE
- 0.12%
- ROIC
- 0.26%
- Revenue
- $0 · 0.00%
- Net Income
- $-1,892,000 · 70.66%
- EPS
- $-77.41 · 71.19%
- Op Income
- $-3,874,000
- FCF YoY
- 58.71%
- 52W High
- $882.86
- 52W Low
- $200.00
- 50D MA
- $417.99
- 200D MA
- $548.55
- Beta
- 1.02
- Avg Volume
- 11
Get TickerSpark's AI analysis on FWPAY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our FWPAY coverage
Recent articles, reports, and earnings notes.
No research on FWPAY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FWPAY report →Similar companies
Peers in the same neighborhood.